OVID
Ovid Therapeutics Inc.
3.10
+
0.11
3.68%
2 x 3.07
1 x 3.13
bid
ask
2 @ 04:00 PM
3.23+0.13 (4.19%)
Bearish
8
Bullish
20
sentiment
2.99
day range
3.13
2.72
52 week range
4.04
Prev Close2.99
Open2.99
Low2.99
High3.13
Volume71.12K
Avg. Volume206.35K
Market Cap219.20M
Inst. Own64.59%
Beta0.69
Short Ratio8.80
Div & Yield0.00 /
EPS-0.74
P/E0.00
1yr Target7.33
50day MA3.21
200day MA3.43
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-03 | 2024-03 | -0.22 | N/A | N/A | N/A |
2024-03-08 | 2023-12 | -0.17 | -0.22 | -0.05 | -29.41% |
2023-11-03 | 2023-09 | -0.18 | -0.16 | 0.02 | 11.11% |
2023-08-04 | 2023-06 | -0.21 | -0.18 | 0.03 | 14.29% |
2023-05-05 | 2023-03 | -0.18 | -0.19 | -0.01 | -5.56% |
2023-03-13 | 2022-12 | -0.19 | -0.16 | 0.03 | 15.79% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-06-13 | JonesTrading | Upgrade | Buy | |
2023-05-01 | Ladenburg Thalmann | Upgrade | Buy | |
2022-08-28 | Citigroup | Upgrade | Neutral | |
2022-05-19 | Citigroup | Upgrade | Neutral | |
2021-08-24 | Citigroup | Upgrade | Neutral | |
2021-04-19 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-02-25 | BERNSTEIN KAREN | Director | 20.00K | Purchase |
2017-05-09 | DURING MATTHEW M.D. | President | 4.68M | Conversion of Exercise of derivative security |
2024-03-17 | LEVIN JEREMY M | Chief Executive Officer | 3.65M | Purchase |
2024-02-21 | PERONE THOMAS MICHAEL | General Counsel | 28.13K | Stock Award(Grant) |
2021-07-13 | RAKHIT AMIT M.D. | President | 726.82K | Sale |
2024-02-21 | RONA JEFFREY A | Chief Financial Officer | 28.13K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | BVF Inc. | 6.85M | 22.47M | 9.70% |
2023-06-29 | EcoR1 Capital, LLC | 6.12M | 20.07M | 8.66% |
2023-06-29 | Rubric Capital Management LP | 5.45M | 17.86M | 7.71% |
2023-06-29 | Blackrock Inc. | 3.41M | 11.18M | 4.83% |
2023-06-29 | Madison Avenue Partners, LP | 3.31M | 10.85M | 4.68% |
2023-06-29 | Vanguard Group Inc | 2.90M | 9.51M | 4.11% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.85M | 6.07M | 2.62% |
2023-08-30 | iShares Russell 2000 ETF | 1.20M | 4.04M | 1.70% |
2023-06-29 | Vanguard Extended Market Index Fund | 695.68K | 2.28M | 0.99% |
2023-07-30 | Fidelity Small Cap Index Fund | 519.63K | 1.87M | 0.74% |
2023-08-30 | iShares Russell 2000 Value ETF | 498.03K | 1.68M | 0.71% |
2023-05-30 | Fidelity Extended Market Index Fund | 271.23K | 960.16K | 0.38% |
This topic has been deleted. Only users with topic management privileges can see it.
-
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
globenewswire.com • -
3 Very Promising Penny Stocks That Are Flying Under the Radar
investorplace.com • -
3 Biotech Stocks Under $10 to Add to Your Buy List
investorplace.com • -
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
globenewswire.com • -
Ovid Therapeutics: Good Entry Point For Investors
seekingalpha.com • -
HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover
investorplace.com • -
8 Biotech Penny Stocks for Investors to Watch
investorplace.com • -
OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today
investorplace.com • -
Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying
benzinga.com • -
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
globenewswire.com • -
Altimmune COVID Update, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com • -
Novavax和武田宣布在日本合作Novavax的COVID-19候选疫苗
businesswire.com • -
武田宣佈2020會計年度第一季業績;確認管理層指引,並提高全年列報營業利潤和列報淨利潤
businesswire.com • -
Ovid Therapeutics: A Full Investment Analysis
seekingalpha.com • -
3 Top Biotech Stocks to Buy Now
finance.yahoo.com • -
Ovid Therapeutics (NASDAQ:OVID) Rating Reiterated by William Blair
thelincolnianonline.com • -
Ovid Therapeutics (NASDAQ:OVID) PT Raised to $9.00
thelincolnianonline.com • -
Two Sigma Advisers LP Purchases 4,200 Shares of Ovid Therapeutics Inc (NASDAQ:OVID)
thelincolnianonline.com • -
Ovid Therapeutics (NASDAQ:OVID) Shares Up 5.6% After Analyst Upgrade
thelincolnianonline.com • -
Is Ovid Therapeutics Stock a Buy?
finance.yahoo.com • -
Takeda Pharmaceutical Co Ltd (NYSE:TAK) Shares Acquired by Guggenheim Capital LLC
thelincolnianonline.com • -
How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?
finance.yahoo.com • -
Is Ovid Therapeutics Inc. (OVID) Going to Burn These Hedge Funds?
finance.yahoo.com • -
IPO Update: Nkarta Proposes Terms For $150 Million IPO (Pending:NKTX)
seekingalpha.com • -
Biotech firm Carmine Therapeutics inks US$900m deal with Takeda Pharmaceuticals
businesstimes.com.sg • -
Local gene therapy firm inks $1.2b deal with pharma giant
straitstimes.com • -
Ovid Therapeutics Added to Russell 2000® and Russell 3000® Indexes
finance.yahoo.com • -
Voloridge Investment Management LLC Decreases Stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK)
thelincolnianonline.com • -
Takeda India donates Rs 1.2 cr to PM CARES Fund
devdiscourse.com • -
Okta, CrowdStrike, Netskope, and Proofpoint Join Together to Secure Remote Work | | IT Business Net
business.itbusinessnet.com • -
5 of the Best Pharmaceutical Stocks to Buy Right Now
investorplace.com • -
Ovid Therapeutics (OVID) Jumps: Stock Rises 12.4%
finance.yahoo.com • -
Enterome Closes €46.3M Financing Round | FinSMEs
finsmes.com • -
6 Stocks That Could Edge Higher
investing.com • -
Head to Head Analysis: Ovid Therapeutics (NASDAQ:OVID) & Cotinga Pharmaceuticals (NASDAQ:COTQF)
thelincolnianonline.com • -
Implied Volatility Surging for Ovid Therapeutics (OVID) Stock Options
finance.yahoo.com • -
Ovid Therapeutics (NASDAQ:OVID) Shares Gap Up After Analyst Upgrade
thelincolnianonline.com •